Betamethasone dipropionate is under clinical development by Oticara and currently in Phase II for Rhinosinusitis. According to GlobalData, Phase II drugs for Rhinosinusitis have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Betamethasone dipropionate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
Betamethasone dipropionate overview
Betamethasone dipropionate is under development for the treatment of eosinophilic chronic rhinosinusitis (eCRS). It acts by targeting glucocorticoid receptor. It is administered through nasal route.
Oticara overview
Oticara is an developer of therapeutics ear and sinus conditions. The items created are Otic to get otitis externa caused due bacterial and contagious microorganisms. It is headquartered in Austin, Texas, the US.
For a complete picture of Betamethasone dipropionate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
